From pooled phase III data, Crestor has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/ l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (< 3 mmol/ l).
Kasutades Crestoriga annuses 10 mg saavutati seatud ravieesmärgid (LDL- kolesterooli sisaldus veres < 3mmol/ L) ligi 80% patsientidest.